Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

The US Food and Drug Administration announced on Tuesday that it has launched a voluntary pilot program intended to reduce the risks of laboratory-developed tests used to select patients for oncology therapies.

On March 30 2023, Kalorama Information indicates that the global IVD market is now over $124 billion, with operations in more than 20 key healthcare and medical areas, such as infectious disease immunoassays, POC, molecular microbiology, clinical chemistry, etc.

Inex Innovate of Singapore plans to launch a PCR-based endometrial cancer detection test this summer, following interim results from a clinical study with researchers at the Chinese University of Hong Kong that were presented here at the Association of Molecular Pathology 2023 Europe Congress this week.

China-based, blood cancer early detection and monitoring technology company, SeekIn has released new research on its multi-cancer early detection (MCED) test, OncoSeek.

Recently, Genalive, a joint venture between BGI Almanahil Health for Medical Services (a wholly owned subsidiary of BGI Genomics) and Tibbiyah Holding (a wholly owned subsidiary of Saudi Al Faisaliah Group), opened its independent clinical laboratory.

Qiagen on Thursday announced a systematic review and publication of the clinical relevance of test values from its QuantiFeron-TB Gold Plus TB1 and TB2 blood collection tubes.

Breast Cancer Canada said on Thursday that it has launched a new grant program in collaboration with AstraZeneca Canada and Illumina.

On June 15, 2023, the inaugural meeting of Institute of Bioinformatics of Shanghai Academy of Experimental Medicine (hereinafter referred to as "Institute of Bioinformatics") and Gene Sequencing Bioinformatics Research Summit Forum was held in Intercontinental Hotel in Jing'an, Shanghai. Ltd.

Eli Lilly and Verve Therapeutics on Thursday said they have entered into an exclusive research collaboration to advance a preclinical gene-editing therapy for atherosclerotic cardiovascular disease (ASCVD) into the clinical stage.

MGI Tech, a Shenzhen, China-based firm focused on the development and distribution of sequencing instruments and reagents, on Wednesday announced that it has signed a licensing agreement with Xpress Genomics.